SEC Company Response from PAVmed Inc. (PAVM) (CIK 0001624326) (PAVM) — Feb 3, 2017
PAVmed Inc. (PAVM) (CIK 0001624326)
Date: Feb. 3, 2017 · CIK: 0001624326 · Accession: 0001571049-17-000992
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214288
Letter
VIA EDGAR Washington, D.C. 20549 RE: PAVmed Inc. Registration Statement on Form S-1 File No. 333-214288
Dear Mr. Mancuso:
PAVmed Inc. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:00 p.m., February 3, 2017, or as soon thereafter as practicable.
In connection with the Company’s request for acceleration of effectiveness of the above-referenced Registration Statement, the Company acknowledges the following:
(1) Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
(2) The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(3) The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.
Very truly yours,
PAVMED INC.
Show Raw Text
CORRESP
1
filename1.htm
PAVMED INC.
One Grand Central Place, Suite 4600
New York, New York 10165
February 3, 2017
VIA EDGAR
Mr. Russell Mancuso
Branch Chief
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
RE: PAVmed Inc.
Registration Statement
on Form S-1
File No. 333-214288
Dear Mr. Mancuso:
PAVmed Inc. (the “Company”)
hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of
the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:00 p.m., February
3, 2017, or as soon thereafter as practicable.
In connection with the
Company’s request for acceleration of effectiveness of the above-referenced Registration Statement, the Company acknowledges
the following:
(1) Should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission
from taking any action with respect to the filing;
(2) The
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(3) The
Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission
or any person under the federal securities law of the United States.
Very truly yours,
PAVMED INC.
By:
/s/ Lishan Aklog
Name: Lishan Aklog, M.D.
Title: Chief Executive Officer